亿帆医药：在研项目F-652本年度仍处研发进程中，暂未发现减值迹象

Group 1 - The company has confirmed that its self-developed project Yili Shou has recognized intangible assets and made impairment provisions in the 2023 fiscal year, with no signs of impairment detected this year [2] - The company's research project F-652 is still in the development process this year, and no signs of impairment have been found [2]